[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "Received full funding application from the supplier.",
          "fs": "Received full funding application from the supplier.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2014",
          "fs": "Feb 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zreBUAQ"
          },
          "Id": "a0P2P000002zreBUAQ",
          "Event_Date__c": "2014-02-01",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Summary__c": "Received full funding application from the supplier.",
          "Formatted_Date__c": "Feb 2014",
          "Status_History__c": "a132P000000AqaXQAS"
        },
        "change": null
      }
    ],
    "dateString": "Feb 2014",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "&#39;The Subcommittee considered that as tobramycin nebuliser solution was not subsidised in the Pharmaceutical Schedule, and did not have a niche use within hospitals, that it should not be included in a national PML.&#39;",
          "fs": "&#39;The Subcommittee considered that as tobramycin nebuliser solution was not subsidised in the Pharmaceutical Schedule, and did not have a niche use within hospitals, that it should not be included in a national PML.&#39;",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "fs": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "change": null
        },
        "Outcome": {
          "s": "Not recommended for inclusion (HML)",
          "fs": "Not recommended for inclusion (HML)",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-infections-group-minutes-2012-09.pdf \" target=\"_blank\">Hospital Pharmaceuticals Subcommittee minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-infections-group-minutes-2012-09.pdf \" target=\"_blank\">Hospital Pharmaceuticals Subcommittee minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Jun 2011",
          "fs": "Jun 2011",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 7 June 2011.",
          "fs": "Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 7 June 2011.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zre6UAA"
          },
          "Id": "a0P2P000002zre6UAA",
          "Event_Date__c": "2011-06-07",
          "Event_Description__c": "Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 7 June 2011.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-infections-group-minutes-2012-09.pdf \" target=\"_blank\">Hospital Pharmaceuticals Subcommittee minutes</a>",
          "Outcome__c": "Not recommended for inclusion (HML)",
          "Summary__c": "&#39;The Subcommittee considered that as tobramycin nebuliser solution was not subsidised in the Pharmaceutical Schedule, and did not have a niche use within hospitals, that it should not be included in a national PML.&#39;",
          "Formatted_Date__c": "Jun 2011",
          "PTAC_Comments__c": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "Status_History__c": "a132P000000AppdQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Not recommended for inclusion (HML)",
          "fs": "Not recommended for inclusion (HML)",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2012",
          "fs": "Aug 2012",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zre7UAA"
          },
          "Id": "a0P2P000002zre7UAA",
          "Event_Date__c": "2012-08-02",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 2 August 2012.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "Not recommended for inclusion (HML)",
          "Formatted_Date__c": "Aug 2012",
          "Status_History__c": "a132P000000Aq57QAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "Recommended only if cost-neutral to the tobramycin IV preparation at a dose of 160 mg twice daily. Also recommended for patients who have a reaction to the IV tobramycin - see separate application.",
          "fs": "Recommended only if cost-neutral to the tobramycin IV preparation at a dose of 160 mg twice daily. Also recommended for patients who have a reaction to the IV tobramycin - see separate application.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "fs": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "change": null
        },
        "Outcome": {
          "s": "Cost Neutral",
          "fs": "Cost Neutral",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2014-04.pdf\" target=\"_blank\">Respiratory Subcommittee minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2014-04.pdf\" target=\"_blank\">Respiratory Subcommittee minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2014",
          "fs": "Apr 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Respiratory Subcommittee at meeting Wednesday 30 April 2014.",
          "fs": "Clinical advice received from Respiratory Subcommittee at meeting Wednesday 30 April 2014.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zreCUAQ"
          },
          "Id": "a0P2P000002zreCUAQ",
          "Event_Date__c": "2014-04-30",
          "Event_Description__c": "Clinical advice received from Respiratory Subcommittee at meeting Wednesday 30 April 2014.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2014-04.pdf\" target=\"_blank\">Respiratory Subcommittee minutes</a>",
          "Outcome__c": "Cost Neutral",
          "Summary__c": "Recommended only if cost-neutral to the tobramycin IV preparation at a dose of 160 mg twice daily. Also recommended for patients who have a reaction to the IV tobramycin - see separate application.",
          "Formatted_Date__c": "Apr 2014",
          "PTAC_Comments__c": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "Status_History__c": "a132P000000Aqe9QAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Cost Neutral",
          "fs": "Cost Neutral",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2014-08.pdf\" target=\"_blank\">PTAC minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2014-08.pdf\" target=\"_blank\">PTAC minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2014",
          "fs": "Aug 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 August 2014.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 August 2014.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zreGUAQ"
          },
          "Id": "a0P2P000002zreGUAQ",
          "Event_Date__c": "2014-08-14",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 August 2014.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2014-08.pdf\" target=\"_blank\">PTAC minutes</a>",
          "Outcome__c": "Cost Neutral",
          "Formatted_Date__c": "Aug 2014",
          "Status_History__c": "a132P000000AqkrQAC"
        },
        "change": null
      }
    ],
    "dateString": "Jun 2011",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2014",
          "fs": "Apr 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zreDUAQ"
          },
          "Id": "a0P2P000002zreDUAQ",
          "Event_Date__c": "2014-04-30",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "Apr 2014",
          "Status_History__c": "a132P000000AqeBQAS"
        },
        "change": null
      }
    ],
    "dateString": "Apr 2014",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "Tobramycin inhalation solution was not included in the first edition of the Hospital Medicines List. This does not prevent consideration of any future applications, whether for hospital or for community.",
          "fs": "Tobramycin inhalation solution was not included in the first edition of the Hospital Medicines List. This does not prevent consideration of any future applications, whether for hospital or for community.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jul 2013",
          "fs": "Jul 2013",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zreAUAQ"
          },
          "Id": "a0P2P000002zreAUAQ",
          "Event_Date__c": "2013-07-01",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Summary__c": "Tobramycin inhalation solution was not included in the first edition of the Hospital Medicines List. This does not prevent consideration of any future applications, whether for hospital or for community.",
          "Formatted_Date__c": "Jul 2013",
          "Status_History__c": "a132P000000AqQhQAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2014",
          "fs": "May 2014",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zreEUAQ"
          },
          "Id": "a0P2P000002zreEUAQ",
          "Event_Date__c": "2014-05-27",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Formatted_Date__c": "May 2014",
          "Status_History__c": "a132P000000AqhmQAC"
        },
        "change": null
      }
    ],
    "dateString": "Jul 2013",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 2012",
          "fs": "Sep 2012",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zre8UAA"
          },
          "Id": "a0P2P000002zre8UAA",
          "Event_Date__c": "2012-09-25",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Formatted_Date__c": "Sep 2012",
          "Status_History__c": "a132P000000Aq9DQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2014",
          "fs": "Aug 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zreFUAQ"
          },
          "Id": "a0P2P000002zreFUAQ",
          "Event_Date__c": "2014-08-07",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Formatted_Date__c": "Aug 2014",
          "Status_History__c": "a132P000000AqjfQAC"
        },
        "change": null
      }
    ],
    "dateString": "Sep 2012",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "The consultation document proposed that this formulation of tobramycin not be listed in Section H at this time, but did propose listing other formulations, and noted that this would not prevent it from being considered for inclusion at a later date.",
          "fs": "The consultation document proposed that this formulation of tobramycin not be listed in Section H at this time, but did propose listing other formulations, and noted that this would not prevent it from being considered for inclusion at a later date.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/consultation-2012-09-25-pharmacueticals-hospital-community.pdf \" target=\"_blank\">Consultation letter</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/consultation-2012-09-25-pharmacueticals-hospital-community.pdf \" target=\"_blank\">Consultation letter</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Oct 2012",
          "fs": "Oct 2012",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "fs": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zre9UAA"
          },
          "Id": "a0P2P000002zre9UAA",
          "Event_Date__c": "2012-10-29",
          "Event_Description__c": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "Stage__c": "Reviewing Consultation Feedback",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/consultation-2012-09-25-pharmacueticals-hospital-community.pdf \" target=\"_blank\">Consultation letter</a>",
          "Summary__c": "The consultation document proposed that this formulation of tobramycin not be listed in Section H at this time, but did propose listing other formulations, and noted that this would not prevent it from being considered for inclusion at a later date.",
          "Formatted_Date__c": "Oct 2012",
          "Status_History__c": "a132P000000AqAfQAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/consultation-2014-08-07-multiproduct.pdf\" target=\"_blank\">Consultation letter</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/consultation-2014-08-07-multiproduct.pdf\" target=\"_blank\">Consultation letter</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2014",
          "fs": "Aug 2014",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "fs": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zreHUAQ"
          },
          "Id": "a0P2P000002zreHUAQ",
          "Event_Date__c": "2014-08-29",
          "Event_Description__c": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "Stage__c": "Reviewing Consultation Feedback",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/consultation-2014-08-07-multiproduct.pdf\" target=\"_blank\">Consultation letter</a>",
          "Formatted_Date__c": "Aug 2014",
          "Status_History__c": "a132P000000Aqm1QAC"
        },
        "change": null
      }
    ],
    "dateString": "Oct 2012",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": [
      {
        "Summary": {
          "s": "Tobramycin solution for inhalataion is funded from 1 November 2014, in both the community and hospital Schedules. In the community it is subsidised if prescribed for a cystic fibrosis patient and the prescription is endorsed accordingly. In hospital use is restricted to patients who have cystic fibrosis.",
          "fs": "Tobramycin solution for inhalataion is funded from 1 November 2014, in both the community and hospital Schedules. In the community it is subsidised if prescribed for a cystic fibrosis patient and the prescription is endorsed accordingly. In hospital use is restricted to patients who have cystic fibrosis.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/notification-2014-10-10-multiproduct.pdf\" target=\"_blank\">Notification letter</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/notification-2014-10-10-multiproduct.pdf\" target=\"_blank\">Notification letter</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Oct 2014",
          "fs": "Oct 2014",
          "change": null
        },
        "Event_Description": {
          "s": "The funding application has been Approved.",
          "fs": "The funding application has been Approved.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002zreIUAQ"
          },
          "Id": "a0P2P000002zreIUAQ",
          "Event_Date__c": "2014-10-08",
          "Event_Description__c": "The funding application has been Approved.",
          "Stage__c": "Decision",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/notification-2014-10-10-multiproduct.pdf\" target=\"_blank\">Notification letter</a>",
          "Summary__c": "Tobramycin solution for inhalataion is funded from 1 November 2014, in both the community and hospital Schedules. In the community it is subsidised if prescribed for a cystic fibrosis patient and the prescription is endorsed accordingly. In hospital use is restricted to patients who have cystic fibrosis.",
          "Formatted_Date__c": "Oct 2014",
          "Status_History__c": "a132P000000AqndQAC"
        },
        "change": null
      }
    ],
    "dateString": "Oct 2014",
    "collapsed": false,
    "checked": true
  }
]